doi:10.1016/s1357-2725(02)00091-2
Oral administration, when using acetate or amidate-stabilized KLOW formulations, delays onset by 4070 minutes due to gastric transit time and first-pass hepatic metabolism, which reduces bioavailability to approximately 3045%
Supplementary information, Table S3), consistent with the scRNA-seq analysis (Supplementary information, Fig
In the future, beyond considering the thresholds for how far to lower blood pressure, blood pressure management in patients with diabetes will require understanding the additive cardioprotective value of drugs aimed at lowering blood pressure and the quality of blood pressure lowering
Supplementary Tables 12 and 13 and Supplementary Tables 2024 show the top GSEA gene sets for the up- and downregulated genes in siGSTO1 and drug treatment Bru-Seq data sets
The benefits usually outweigh the temporary discomfort